KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Abbott Laboratories (ABT) Operating Expenses (2016 - 2025)

Historic Operating Expenses for Abbott Laboratories (ABT) over the last 17 years, with Q3 2025 value amounting to $9.3 billion.

  • Abbott Laboratories' Operating Expenses rose 610.76% to $9.3 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $36.1 billion, marking a year-over-year increase of 465.49%. This contributed to the annual value of $35.1 billion for FY2024, which is 444.23% up from last year.
  • Per Abbott Laboratories' latest filing, its Operating Expenses stood at $9.3 billion for Q3 2025, which was up 610.76% from $9.1 billion recorded in Q2 2025.
  • Abbott Laboratories' Operating Expenses' 5-year high stood at $9.3 billion during Q3 2025, with a 5-year trough of $8.2 billion in Q1 2023.
  • Moreover, its 5-year median value for Operating Expenses was $8.7 billion (2024), whereas its average is $8.7 billion.
  • Its Operating Expenses has fluctuated over the past 5 years, first skyrocketed by 3267.73% in 2021, then tumbled by 829.34% in 2023.
  • Quarter analysis of 5 years shows Abbott Laboratories' Operating Expenses stood at $9.1 billion in 2021, then decreased by 3.33% to $8.8 billion in 2022, then decreased by 3.71% to $8.5 billion in 2023, then increased by 7.11% to $9.1 billion in 2024, then rose by 2.75% to $9.3 billion in 2025.
  • Its last three reported values are $9.3 billion in Q3 2025, $9.1 billion for Q2 2025, and $8.7 billion during Q1 2025.